1.8 Outlook 2020

1.8 Outlook 2020

For 2020, UCB is are aiming for revenues in the range of € 5.05-5.15 billion – thanks to the current core product growth and new patient populations being served. UCB will continue to advance its strong development pipeline to offer potential new solutions for patients and complement with external opportunities.

Hence, the underlying profitability, recurring EBITDA in the range of 28-29% of revenue will reflect the high R&D investment level. Core earnings per share are therefore expected in the range of € 4.80-5.20 based on an average of 187 million shares outstanding.

The figures for the outlook 2020 as mentioned above are calculated on the same basis as the actual figures for 2019; they will be updated upon closing of the planned Ra Pharma acquisition.